Skip to main
TRDA

Entrada Therapeutics (TRDA) Stock Forecast & Price Target

Entrada Therapeutics (TRDA) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entrada Therapeutics Inc. is poised for a positive outlook due to its innovative Endosomal Escape Vehicle (EEV)-therapeutics that target intracellular delivery for neuromuscular and ocular diseases, fostering the potential for superior clinical outcomes. The company's candidate, ENTR-601-44, has demonstrated the potential for significant dystrophin restoration, outperforming competitive therapies such as AOC 1044, which may fulfill an unmet need in the Duchenne muscular dystrophy market and lead to robust adoption. Furthermore, the observed exponentially increasing mean prices for therapeutics in this space suggest a lucrative market environment that could enhance Entrada's revenue potential, should its therapies gain approval and market access.

Bears say

Entrada Therapeutics Inc faces a negative outlook primarily due to substantial risks associated with its clinical programs, particularly the potential failure of both its Endosomal Escape Vehicle (EEV)-therapeutics and the partnered program VX-670. Concerns include unexpected safety issues, lower-than-anticipated efficacy translating from preclinical to clinical stages, and regulatory hurdles that may complicate approval processes, especially in the context of the Duchenne Muscular Dystrophy (DMD) pathway. Additionally, a lack of established biomarker and functional endpoints for VX-670 could prolong the approval timeline, intensifying the risk of negative sentiment and further downward pressure on stock valuation.

Entrada Therapeutics (TRDA) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entrada Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entrada Therapeutics (TRDA) Forecast

Analysts have given Entrada Therapeutics (TRDA) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Entrada Therapeutics (TRDA) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entrada Therapeutics (TRDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.